Matthias Danne

Matthias Danne inquired about the recently lowered cell therapy wind-down costs and whether Galapagos anticipates further reductions in these costs in the future.

Answer

Head of Investor Relations Sofie Van Gijsel stated that while they are not providing future guidance, they will update on costs in future calls. She confirmed the EUR 25 million reduction from the prior guidance range and noted that updates would be provided as the wind-down progresses.